Caxton Associates LP Syndax Pharmaceuticals Inc Transaction History
Caxton Associates LP
- $2.65 Billion
- Q3 2024
Shares
3 transactions
Others Institutions Holding SNDX
# of Institutions
229Shares Held
89.5MCall Options Held
1.01MPut Options Held
692K-
Black Rock Inc. New York, NY7.91MShares$123 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.84MShares$90.7 Million9.23% of portfolio
-
Wellington Management Group LLP Boston, MA4.99MShares$77.4 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.89MShares$75.8 Million0.0% of portfolio
-
Eversept Partners, LP New York, NY4.11MShares$63.7 Million6.25% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $878M
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...